Deals
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Coherus Completes $50m Share Offer To Novel Partner Junshi Biosciences
Coherus BioSciences has sold a little under 2.5 million shares to partner Junshi Biosciences, giving the firm additional capital following a large debt financing last year.
Alvogen’s Lotus Bags $50m Investment To Boost Access In Asia
Lotus Pharmaceuticals aims to build a stronghold in Thailand and beyond, after the Alvogen subsidiary announced a partnership with a subsidiary of Thai state-owned conglomerate PTT, which includes a $50m capital injection.
PlantForm Strikes Deal For Brazilian Pembrolizumab
Canada’s PlantForm has struck a deal with Brazil’s Bio-Manguinhos/Fiocruz to develop a biosimilar pembrolizumab rival to Merck’s Keytruda for the Brazilian market and potentially beyond.
Prestige And Pharmapark Add Bevacizumab To Russia Collaboration
Russia’s Pharmapark has added Prestige BioPharma’s HD204 biosimilar bevacizumab product to the firms’ commercialization partnership, two years after kicking off the partnership with trastuzumab.
Biogen Delves Deeper Into Biosimilars With Tocilizumab Partnership
Biogen has broken new ground in its biosimilar endeavors, expanding beyond its partnership with its part-owned Samsung Bioepis company by agreeing a deal for rights to Bio-Thera Solutions’ BAT1806 biosimilar Actemra/RoActemra (tocilizumab) candidate.
ANI Picks Up US Dermatology Brands From Sandoz
ANI Pharmaceuticals has added to its branded portfolio by acquiring several dermatology brands from Sandoz in the US.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.